Artigos de revistas sobre o tema "B-060"
Siga este link para ver outros tipos de publicações sobre o tema: B-060.
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "B-060".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
1
Sawyer, Eileen K., Sander Gielen, Jaap Twisk, Alison Long e Robert Gut. "Clearance of Vector DNA Following Systemic Administration of AAV5-hFIX or AAV5-hFIX Padua in Patients with Severe or Moderate-Severe Hemophilia B". Blood 134, Supplement_1 (13 de novembro de 2019): 2062. http://dx.doi.org/10.1182/blood-2019-129786.
Texto completo da fonteResumo:
Introduction Current adeno-associated viral (AAV) vector-based gene therapy strategies for hemophilia rely on systemic administration of the vector. Durable expression of the transgene over the span of years has been reported from several trials, yet information on the clearance of vector material from bodily fluids is still limited and monitoring of "shedding" is required during trials despite lack of evidence of environmental or transmission risk. Here, we examined the magnitude and duration of the presence of vector DNA in participants from a Phase I/II study of an AAV5-hFIX wildtype construct (AMT-060; NCT02396342) and from a Phase IIb study utilizing the enhanced version, AAV5-hFIX Padua (AMT-061; NCT03489291). Methods Adult male participants with severe or moderately severe hemophilia B received a single intravenous infusion of either AMT-060 at 5x1012 genome copies(gc)/kg (low dose) or 2×1013 gc/kg (high dose), or AMT-061 at 2x1013gc/kg in one of two ongoing trials. Assessments in both trials included efficacy and safety outcomes as well as vector shedding in whole blood and semen. Vector shedding was also measured in nasal secretions, feces, urine, and saliva in participants receiving AMT-060. Vector shedding was analyzed using a validated quantitative real time polymerase chain reaction (qPCR) based assay measuring presence of vector DNA in the bodily fluids. Vector clearance was reached when vector DNA was either zero or below the limit of detection (LOD) for three consecutive measurements. The range in time to the first and the third consecutive negative measurement for each dose group are provided. Results Treatment with AMT-060 resulted in sustained improvement in FIX activity for up to 3.5 years [Mean FIX activity was 5.1% (low dose group at 3.5 years) and 7.5% (high dose group at 3 years)] and treatment with AMT-061 resulted in mean FIX activity of 45% over 36 weeks. AMT-060 and AMT-061 reduced the mean number of annualized bleeds by between 82% and 100% respectively. AMT-060 reduced the requirement for exogenous FIX administration by 86% and was abrogated with AMT-061. Both AAV5-hFIX and AAV5-hFIX Padua were safe and well tolerated and no unexpected TRAEs have been observed with longer-term follow up. Table 1 describes the time in weeks to the first and last of three consecutive measures of vector DNA of either zero or <LOD for all bodily fluids for AMT-060 and AMT-061. AMT-060 at the higher dose was cleared from semen, feces, urine, nasal secretions and saliva in all participants by week 64 (range 7-64 weeks). In blood, the lower dose of AMT-060 was cleared in all participants by 3 years (range 1.0-3.0 years). The higher AMT-060 dose was cleared in 4 of 5 participants by 2.5 years (range 1.8-2.5 years), and while below the LOD in the 5th participant by year 3, had not achieved the definition of vector clearance. With AMT-061, vector DNA were <LOD or below the lower limit of quantification in blood in all 3 participants by weeks 36-40 and in semen by week 26 in 2 of 3 participants but had not achieved the definition of vector clearance. Conclusions Post-AMT-060 treatment, vector DNA was undetectable in all participants in the high dose group by 10 months and considered cleared by 16 months in all bodily fluids except blood. AMT-060 was cleared from the blood in 100% of participants in the low dose group at 3 years and 80% of participants in the high dose group by 2.5 years. As expected, AMT-061 vector DNA was detectable at 36 weeks in blood and in the semen of 1 of 3 participants, although clearance had not yet been established in the remaining participants. The presence of vector DNA in bodily fluids assessed was not associated with any adverse safety or efficacy findings. Disclosures Sawyer: Uniqure BV: Employment. Gielen:uniQure Biopharma: Employment. Twisk:uniQure Biopharma: Employment. Long:Uniqure BV: Employment. Gut:Uniqure BV: Employment.
2
Heuser, M., P. Andrieux, S. Petit e H. Stanjek. "Iron-bearing smectites: a revised relationship between structural Fe, b cell edge lengths and refractive indices". Clay Minerals 48, n.º 1 (março de 2013): 97–103. http://dx.doi.org/10.1180/claymin.2013.048.4.06.
Texto completo da fonteResumo:
AbstractStructural iron in smectites correlates with the cell edge length b and increases the refractive index. The cell edge length b is usually obtained from the position of the (060) reflection, but in this work we show that such b values differ from the values obtained from Rietveld fits because contributions from (hkl) reflections shift the position of the (060) reflection. The correlation between Fe and cell edge length b was significant (r2 > 0.99); the relationship is b [Å] = 8.9977(0.0035) + 0.1117(0.0032) × Fetot. Furthermore, we present for the first time measurements of the refractive index n of Fe-bearing smectites, applying a recently published turbidity method (Weidler & Friedrich, 2007). The refractive index correlates both with structural iron (r2 = 0.64) and with b (r2 = 0.94).
3
Leebeek, Frank, K. Meijer, Michiel Coppens, Peter Kampmann, Robert Klamroth, Roger Schutgens, Giancarlo Castaman et al. "Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy". Blood 132, Supplement 1 (29 de novembro de 2018): 3476. http://dx.doi.org/10.1182/blood-2018-99-109995.
Texto completo da fonteResumo:
Abstract Introduction: AMT-060 consists of an adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized wildtype human factor IX (FIX) gene under control of a liver-specific promoter. We have previously reported on the safety and efficacy of AMT-060 gene therapy at 2 dose levels in adults with moderate-severe or severe hemophilia B with up to 1-year follow-up. Here we present longer-term follow-up data on reductions in annualized bleed rates and FIX consumption up to 2.5 years post-treatment. Methods: Multi-national, open-label, dose-escalating study in participants (pts) with FIX activity ≤2 % of normal, and a severe bleeding phenotype (NCT02396342). Pts received either 5x1012 gc/kg (Cohort 1, n=5) or 2×1013 gc/kg (Cohort 2, n=5) of AMT-060 iv. Duration of follow-up was 2.5 and 2 years in Cohort 1 and Cohort 2, respectively. Efficacy assessments include FIX activity (measured ≥10 days after use of exogenous FIX), reduction of FIX use, and annualized total bleeding rates. Bleeds were counted for each individual patient starting after discontinuation of prophylaxis post-AMT-060. For Cohort 1, exogenous FIX use and bleeds for "year 3" are presented as a calculated annualized mean using data captured between 2 and 2.5 years. Safety assessments include treatment-related adverse events, immunological and inflammatory biomarkers. Results: Nine pts with severe (FIX <1 %) and 1 with moderate-severe (FIX 1.5 %) hemophilia B were enrolled and received AMT-060. Nine were receiving exogenous FIX prophylaxis and one was receiving on-demand exogenous FIX. Mean FIX activity over the course of follow up was 4.9 % in Cohort 1 and 7.4% in Cohort 2. Disease severity improved in all pts: from severe to mild (n=6), severe to moderate (n=3), and moderate to mild (n=1). Eight of nine pts on FIX prophylaxis at study entry discontinued use after AMT-060 infusion. In Cohort 1, annualized exogenous FIX use (excluding use for surgeries) decreased from a pre-treatment cumulative total of 1,562,000 IU by 85%, 96% and 93% for years 1, 2 and 3 of follow-up (n=4, excluding patient who remained on prophylaxis post-treatment). In Cohort 2, exogenous FIX use was reduced from a pre-treatment cumulative total of 866,000 IU by 78% and 93% for years 1 and 2 of follow-up (n=5). Mean annualized total bleeds decreased from 14.4 in the year prior to AMT-060 to 7.6, 2.8 and 7.8, in years 1, 2, and 3 of follow-up in Cohort 1. Among the three patients with FIX activity >5% in Cohort 1, a single bleed was reported in year 2 and no bleeds were reported to data cut-off in year 3. For the two patients with FIX activity <5%, one patient with mean FIX activity of 4-4.3% reported 4 bleeds for year 2 and 4 bleeds to data cutoff in year 3, while the patient remaining on prophylaxis reported 8 and 9 bleeds during the same period. In Cohort 2, mean annualized total bleeds were reduced from a pre-therapy mean of 4.0 to 1.5 and 0.5 in years 1 and 2, respectively. One pt in Cohort 2 was not included in the calculation as historical bleed data was not available; he experienced one traumatic bleed approximately 7.5 months after the discontinuation of prophylaxis. No pts developed inhibitors to FIX and there were no detectable signs of sustained AAV5 capsid-specific T-cell activation. Fourteen treatment-emergent adverse events were reported in the first 3.5 months after treatment, including three patients who experienced transient mild elevations in alanine aminotransferase as previously disclosed. There were no additional treatment-related adverse events reported during this additional follow-up period up to 2.5 years post-treatment. Conclusions: Stable endogenous FIX concentrations >4% have now been observed out to 2.5 years post-treatment with AMT-060. In addition, we have observed continued reductions in annualized bleeds to near zero with the higher dose of AMT-060, and a 78-93% reduction in exogenous FIX use. The lack of additional safety concerns or treatment-related adverse events over the longer study period, including no recurring changes in ALT, support the continued development and transition of AMT-060 to AMT-061, which will use the same AAV5 vector to deliver the 2×1013 gc/kg dose with the enhanced Padua transgene, which is anticipated to increase FIX activity 6-8 fold. Disclosures Leebeek: CSL Behring: Research Funding; Uniqure: Research Funding; Baxalta/Shire: Research Funding. Meijer:BMS: Honoraria; Aspen: Honoraria; Boehringer Ingelheim: Honoraria; Pfizer: Research Funding; Sanquin: Honoraria, Research Funding; Bayer: Honoraria, Other: Travel support, Research Funding; UniQure: Research Funding. Coppens:Bayer: Honoraria, Other: Non-financial support, Research Funding; CSL Behring: Honoraria, Other: non-financial support, Research Funding; Uniqure BV: Research Funding. Kampmann:Uniqure BV: Research Funding. Klamroth:Baxalta (Shire), Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire, and SOBI: Consultancy; Baxalta (Shire), Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire, and SOBI: Research Funding. Schutgens:Baxalta/Shire: Research Funding; Novo Nordisk: Research Funding; Bayer: Research Funding; CSL Behring: Research Funding; Pfizer: Research Funding; Uniqure BV: Research Funding. Seifried:Medac: Other: BSD owns IP and is contract manufacturer; Uniqure BV: Research Funding. Schwaeble:UniQure BV: Research Funding. Bonig:Kiadis Pharma: Consultancy. Sawyer:Uniqure BV: Employment. Miesbach:Bayer, Shire, Biotest, pfizer, Octapharma, LFB, CSL Behring, SOBI, Biogen, BPL: Consultancy; UniQure BV: Research Funding; Novo Nordisk: Consultancy, Research Funding.
4
Munoz, Ernesto, e Allison Carilli. "CLO23-060: Extranodal Presentation of Double Hit High Grade B Cell Lymphoma". Journal of the National Comprehensive Cancer Network 21, n.º 3.5 (31 de março de 2023): CLO23–060. http://dx.doi.org/10.6004/jnccn.2022.7219.
Texto completo da fonte
5
Leebeek, Frank W. G., Marco Tangelder, Karina Meijer, Giancarlo Castaman, Federica Cattaneo, Michiel Coppens, Peter Kampmann et al. "Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B". Blood 128, n.º 22 (2 de dezembro de 2016): 2314. http://dx.doi.org/10.1182/blood.v128.22.2314.2314.
Texto completo da fonteResumo:
Abstract Introduction: The development of gene transfer for hemophilia is advancing rapidly and offers the potential to shift the disease severity from severe to mild with a single treatment. AMT-060 consists of an AAV5 vector with a gene cassette containing an LP1 liver specific promoter and codon-optimized wild type hFIX gene that has previously been shown to result in durable increases in FIX activity of at least 4 years1. This phase 1/2 study aims to investigate the safety and efficacy of AMT-060 in adult patients with severe hemophilia B. Methods: This is a multi-national, multi-center, open-label, dose-escalating study in patients with FIX activity ≤ 2% of normal, and a severe bleeding phenotype. To be eligible, patients had to require either prophylactic exogenous FIX, or on-demand exogenous FIX with more than 4 bleeds per year or suffer from hemophilic arthropathy. Ten patients were treated in two subsequent, escalating dose cohorts, with AMT-060 5x 1012 gc/kg (n=5) or 2x 1013 gc/kg (n=5). Patients received AMT-060 via a single intravenous infusion over 30 minutes. Efficacy assessments include endogenous FIX activity, measured at least 10 days after the most recent administration of exogenous FIX; reduction of exogenous FIX use; and annualized spontaneous bleeding rates. Safety assessments include treatment related adverse events and immunological assessments, including T-cell response to capsid antigens. Results : There were no screen failures for pre-existing antibodies against AAV5. The age of enrolled patients ranged from 33 to 72 years. At enrollment, nine patients were on FIX prophylaxis, and one patient in the high dose cohort used on-demand FIX therapy. At the time of submission, all ten patients have received AMT-060. The mean of all endogenous FIX activity values after cessation of prophylaxis in the low-dose cohort was 5.4% (95% CI 5.0-5.8%, range 3.1-6.7%; n=4), and stable during the 39 weeks of follow-up. Four out of five patients in the low-dose cohort were able to stop FIX prophylaxis. These patients demonstrated a mean reduction in annualized total FIX usage of 82% after treatment with AMT-060. For all five patients in the low-dose cohort, the mean annualized total FIX usage declined 75% after treatment with AMT-060. Following AMT-060 administration, one patient in the lower dose cohort had a mild, asymptomatic, elevation of ALT at week 10 that resolved with a seven weeks course of tapering prednisolone. No change in FIX activity, and no T-cell response or other possibly associated immunogenicity or inflammatory abnormalities were seen during the ALT elevation. Efficacy and safety results will be updated up to 52 weeks of follow up for the low-dose cohort. Initial efficacy and safety results from the higher-dose cohort up to 26 weeks of follow up will also be presented. Conclusions: Follow up of patients with severe hemophilia B who received either the low or higher dose of AMT-060 is ongoing. A single infusion of AMT-060 was generally well-tolerated. FIX activity increased to levels sufficient to provide endogenous prophylaxis in four of five patients in the low-dose cohort, relieving them from the need for exogenous FIX prophylaxis and resulting in marked decrease of FIX usage. 1Nathwani et al. NEJM 2014; 371:1994-2004 Disclosures Leebeek: UniQure: Consultancy; Netherlands Hemophilia Foundation: Research Funding; CSL Behring: Research Funding; Baxter: Research Funding. Tangelder:uniQure: Employment. Meijer:Baxter: Research Funding; Bayer: Honoraria, Research Funding; Pfizer: Research Funding; Sanquin: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria; Bristol-Myers Squibb: Honoraria. Castaman:Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Baxalta-Shire: Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees; Kedrion: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees. Cattaneo:Chiesi: Employment. Coppens:Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; BMS/Pfizer: Consultancy, Honoraria, Research Funding; Sanquin: Consultancy, Honoraria, Research Funding. Klamroth:SOBI: Other: honoraria for advisory boards and speaker fees; uniqure: Other: honoraria for advisory boards and speaker fees; pfizer: Other: honoraria for advisory boards and speaker fees; NovoNordisk: Other: honoraria for advisory boards and speaker fees; Octapharma: Other: honoraria for advisory boards and speaker fees; Baxalta: Other: honoraria for advisory boards and speaker fees ; Bayer: Other: honoraria for advisory boards and speaker fees; Biogen Idec: Other: honoraria for advisory boards and speaker fees; CSL Behring: Other: honoraria for advisory boards and speaker fees. Schutgens:CSL Behring: Research Funding; Sanquin: Research Funding. Hendriks:uniQure: Employment. Corzo:uniQure: Employment. Miesbach:Grifols: Honoraria; CSL Behring: Research Funding; Pfizer: Honoraria; uniQure: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; LFB: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Baxalta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Biotest: Honoraria, Research Funding; Octapharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
6
Semenova, Lioubov I., Alexander N. Sobolev, Brian W. Skelton e Allan H. White. "Structural Systematics of Rare Earth Complexes. XV Tris(2,2′:6′,2″-terpyridine)lanthanoid(III) Tris(perchlorate) Complexes". Australian Journal of Chemistry 52, n.º 6 (1999): 519. http://dx.doi.org/10.1071/ch98046.
Texto completo da fonteResumo:
Room-temperature single-crystal X-ray structure determinations of the 1 : 3 adducts of the trivalent lanthanoid perchlorates with 2,2′:6′,2″-terpyridine (‘tpy’) as crystallized from acetonitrile are recorded. The Ln = La complex is the only one of its structural type, being modelled as La(ClO4)3/tpy/MeCN/H2O (1 : 3 : 2 :2/3), trigonal P 3c1, Z = 6, a 13·063(7), c 53·04(4) Å, recorded on an interim basis, with conventional R on |F| 0·081 for No 2889 ‘observed’ (I >3σ(I)) reflections. For Ln = Ce, (Pr, Sm,) Eu and, by presumption, other intermediate members, a monosolvate is found, monoclinic P 21/n, a ≈ 9·3, b ≈ 21·1, c ≈ 24·7 Å, β ≈ 91°, Z = 4, R being 0·045, (0·060, 0·049,) 0·047 for No 4420, (4199, 3931,) 3713. The Ln = Eu adduct has also been obtained unsolvated in a form representative of Ln = Eu, Lu and, by presumption, intermediate members, as well as Y, which is monoclinic C 2/c, Z = 4, R being 0·051, 0·044, 0·061 for No 4386, 4407, 3713. All monoclinic systems are of the form [Ln(tpy)3] (ClO4)3(.S), Ln being nine-coordinate, and in the case of the C 2/c phase lying on a crystallographic 2 axis. The Ln = La adduct was modelled with three independent cations, all with crystallographic 3 symmetry, two with their coordination number augmented by the approach of solvent along the 3 axis.
7
Smirnova, D., E. Sloeva, N. Kuvshinova, A. Krasnov, M. Ustinov, D. Romanov e G. Nosachev. "P.2.b.060 Language phenomenon in the diagnostic criteria of mild depression". European Neuropsychopharmacology 23 (outubro de 2013): S354—S355. http://dx.doi.org/10.1016/s0924-977x(13)70559-5.
Texto completo da fonte
8
Lee, Shinduk, Marcia Ory, Deborah Vollmer Dahlke, Tiffany Shubert, Steve Popovich e Matthew Smith. "Conservation of Resources Theory: Technology and Caregiver Strain". Innovation in Aging 4, Supplement_1 (1 de dezembro de 2020): 468. http://dx.doi.org/10.1093/geroni/igaa057.1515.
Texto completo da fonteResumo:
Abstract Using the Conservation of Resources Theory, this study examined how caregiver strain was influenced by care recipients’ use of falls alert wearables. Online survey data from 486 unpaid caregivers for adults aged 50 and older were analyzed. Structural equation modeling was used to test the following hypotheses: (1) caregivers with fewer financial resources would engage in fewer resource conservation strategies (e.g., care recipients’ use of falls alert wearables); (2) resource conservation strategy engagement would be associated less resource loss; and (3) the effect of resource conservation strategies on caregiver strain would be less salient than the effect of resources used on caregiving (e.g., time and social support). The hypothesized model had a good model fit (CFI=.910), with SRMR (.060) and RMSEA (.062) being close to .05. All hypothesized paths were statistically-significant, except for the direct effect of using falls alert wearables on social support (p=.076) and caregiver strain (p=.135). As hypothesized, higher income was associated with greater likelihood of using falls alert wearables (b=.10, p>.022). Technology use was associated with less time spent on caregiving (b=-.16, p<.001) and had statistically-significant indirect effects on caregiver strain (b=-.03, p=.008). The total effect of using falls alert wearables (b=.04, p=.394) on caregiver strain was less powerful than the effect of time (b=.20, p<.001) or social support (b=-.28, p<.001). Study findings suggest the benefits of using falls alert wearables to alleviate time-related burdens and downstream caregiver strain among unpaid caregivers. Future efforts should investigate the relative advantage of wearables for other caregiving purposes.
9
Leebeek, Frank W. G., Karina Meijer, Michiel Coppens, Peter Kampmann, Robert Klamroth, Roger Schutgens, Giancarlo Castaman et al. "AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years". Blood 136, Supplement 1 (5 de novembro de 2020): 26. http://dx.doi.org/10.1182/blood-2020-139225.
Texto completo da fonteResumo:
Background: Gene therapy aims to provide long-term therapeutic benefit from a single administration. AMT-060 is an adeno-associated virus serotype 5 (AAV5) vector with a codon-optimized wildtype human factor IX (FIX) gene and liver-specific promoter. AMT-060 is being evaluated in an ongoing study of 10 participants with severe/moderate-severe hemophilia B (Phase 1/2 study, NCT02396342) over 5 years. Aim: To describe efficacy and safety outcomes from an analysis at up to 5-years post-AMT-060. Methods: Adult males with FIX activity ≤2% and a severe bleeding phenotype received a single intravenous infusion of AMT-060 (5x1012 gc/kg, Cohort 1, n=5) or (2×1013 gc/kg, Cohort 2, n=5). Assessments included FIX activity, FIX replacement use, annualized bleeding rate (ABR), treatment-related adverse events (TRAE), immunological and inflammatory biomarkers up to 5 years (Cohort 1) and 4.5 years (Cohort 2). Results: As of November 2019, for Cohort 1 the mean FIX activity (at 4.0 years) was 5.1% as compared to 4.4% in the first year, 6.8% in the second year, 7.3% in the third year and 7.0% in the fourth year. Mean FIX activity for Cohort 2 was 7.5% as compared to 7.1% in the first year, 8.4% in the second year 7.9% in the third year, and 7.4% in the fourth year. Eight of 9 participants using prophylaxis at baseline were able to discontinue use. During the last 12, and 6 months of observation respectively, the mean annualized bleed rate (ABR) was 3.3. for Cohort 1 and 0.0 for Cohort 2. These represent, respectively, a reduction in mean ABR to the year prior to treatment of 77% and 100% for Cohort 1 and Cohort 2. During this same period the consumption of FIX replacement therapy declined 90% and 100% relative to pre-treatment, respectively for Cohort 1 and Cohort 2. No participants developed FIX inhibitors or signs of sustained AAV5 capsid-specific T-cell activation. As previously reported, TRAE were mainly reported in the first 3.5 months after treatment, including three participants who experienced transient mild elevations in alanine aminotransferase. One additional TRAE (joint swelling post-exercise) was observed during the last 12 months of observation post-treatment. Updated data, up to 5-years of observation, will be presented for the first time. Conclusions: Long-term stable endogenous FIX activity and reductions in ABR and FIX replacement use were sustained over multiple years following a single treatment with AMT-060. There were no additional safety concerns with longer term follow-up. This data supports the ongoing Phase 3 study of the enhanced construct etranacogene dezaparvovec (AMT-061), which encodes the highly active Padua FIX variant. Disclosures Meijer: Bayer: Research Funding; Sanquin: Research Funding; Pfizer: Research Funding; Bayer: Speakers Bureau; Sanquin: Speakers Bureau; Boehringer Ingelheim: Speakers Bureau; BMS: Speakers Bureau; Aspen: Speakers Bureau; Uniqure: Consultancy. Kampmann:Uniqure: Speakers Bureau; Shire Pharmaceuticals: Speakers Bureau. Klamroth:CSL Behring: Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Octapharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Takeda/Shire: Consultancy, Research Funding, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Biotest: Speakers Bureau; Grifols: Speakers Bureau; Biomarin: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy, Research Funding, Speakers Bureau. Castaman:Novo Nordisk: Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau; Pfizer: Honoraria, Research Funding; Ablynx: Honoraria; Alexion: Honoraria; Bayer: Honoraria; CSL Behring: Honoraria, Research Funding; Kedrion: Speakers Bureau; Sobi: Honoraria, Research Funding, Speakers Bureau; Uniqure: Honoraria, Membership on an entity's Board of Directors or advisory committees; Werfen: Speakers Bureau; Baxalta/Shire: Honoraria. Bönig:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Healthineers: Current equity holder in publicly-traded company; Sandor-Hexal: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Polyphor: Research Funding; Miltenyi: Honoraria, Research Funding; Erydel: Research Funding; Chugai: Honoraria, Research Funding; Bayer: Research Funding; Terumo BCT: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kiadis: Honoraria; Uniqure: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Stage: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Fresenius: Honoraria; medac: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Sawyer:uniQure: Current Employment. Miesbach:UniQure: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BioMarin Pharmaceutical Inc: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. OffLabel Disclosure: AMT-060 = AAV5 vector gene therapy in subjects with moderate to severe hemophilia B
10
Lensink, Cornelis, e Graeme J. Gainsford. "Synthesis and Structure of Two Isomers of Di(indenyl)phenylphosphine Sulfide". Australian Journal of Chemistry 51, n.º 8 (1998): 667. http://dx.doi.org/10.1071/c97210.
Texto completo da fonteResumo:
Dichlorophenylphosphine reacts with indenyllithium in tetrahydrofuran followed by sulfur to yield di(1H-inden-3-yl)phenylphosphine sulfide (2). The same reaction sequence in toluene yields di(1H-inden-1-yl)phenylphosphine sulfide (3) as a mixture of (±) and two meso isomers. The structures of (2) and (±)-(3) were determined [(2): C24H19PS, Mr 370·42, monoclinic, P21/n, a 14·329(4), b 7·0936(10), c 19·405(5) Å, β 99·18(2)°, Z 4, R 0·060 for 2422 observed reflections; (3): C24H19PS, Mr 370·42, monoclinic, P21/n, a 9·521(5), b 16·223(8), c 12·930(6) Å, β 107·41(3)°, Z 4, R 0·105 for 923 reflections].
11
Delaigue, Xavier, Jack M. Harrowfield, M. Wais Hosseini, Mauro Mocerino, Brian W. Skelton e Allan H. White. "'Soft' Calixarenes–Structural Aspects of Calixarene Allyl Ethers and of Thiacalixarene Synthesis". Australian Journal of Chemistry 51, n.º 2 (1998): 111. http://dx.doi.org/10.1071/c97095.
Texto completo da fonteResumo:
Syntheses and room-temperature single-crystal X-ray structure determinations are recorded for an array of p-t-butylcalix[n]arenes, n = 4 or 6, diversely functionalized at the phenolic oxygen atoms: the 1,3-diallyl 2,4-dimethyl ether for n = 4 (1), the hexaallyl ether for n = 6 (2), and the 1,3-dibenzyl 2,4-bis(dimethylthiocarbamoyl) derivative for n = 4 (3), with a view to establishing ligand baseline conformations for subsequent metal complexation studies, and for exploring any inclusion properties. Compound (1) is monoclinic, P21/c, a 16·751(9), b 20·772(7), c 27·91(1) Å, β 99·39(4)°, Z = 8, conventional R on |F| being 0·060 for No 4396 'observed' (I > 3σ(I )) reflections. Compound (2) is triclinic, P-1, a 19·63(2), b 14·57(2), c 14·188(9) Å, α 107·84(8), β 93·26(7), γ 99·48(10)°, Z = 2, R 0·067 for No 7315. Compound (3), as its methanol monosolvate, is triclinic, P-1, a 15·592(4), b 15·17(3), c 14·31(2) Å, α 88·8(1), β 64·3(1), γ 75·7(1)°, Z = 2, R 0·076 for No 3802. The conformation of (1) is similar to that previously established for an analogue in which two of the t-butyl groups were absent; the conformation of (2) is that of a flattened 1,2,3-alternate form, the asymmetric unit being a pair of half (centrosymmetric) dimers; the conformation of (3) is 1,3-alternate.
12
Yoshizaki, A., T. Fukasawa, Y. Asano, T. Kitamori e S. Sato. "060 The cytokine production of autoantigen-reactive B cells associates with pathogenesis in systemic sclerosis". Journal of Investigative Dermatology 138, n.º 5 (maio de 2018): S10. http://dx.doi.org/10.1016/j.jid.2018.03.064.
Texto completo da fonte
13
Harrowfield, Jack M., Raj Pal Sharma, Todd M. Shand, Brian W. Skelton e Allan H. White. "Structural Systematics of 2/4-Nitrophenoxide Complexes of Closed-Shell Metal Ions. I 2-Nitrophenoxides of Group 1". Australian Journal of Chemistry 51, n.º 8 (1998): 707. http://dx.doi.org/10.1071/c97098.
Texto completo da fonteResumo:
Room-temperature, single-crystal X-ray studies are recorded for the variously hydrated Group 1 metal derivatives of 2-nitrophenol (2-npH = C6H5NO3). A provisional determination is reported for Li(2-np).½H2O, set as monoclinic, P21/c, a 3·535(3), b 15·06(1), c 24·42(2) Å, β 91·7(1)°, Z = 8, conventional R on F currently 0·18 for No 875 ‘observed’ (I > 3σ(I)) reflections. Na(2-np).H2O is monoclinic, C2/c, a 34 ·23(2), b 3·624(4), c 35·48(2) Å, β 91·24(4)°, Z = 24, R 0·060 for No 1371. Rb(2-np).½ H2O is monoclinic, C2/c (isomorphous with the previously determined potassium analogue), a 25·269(9), b 5·381(5), c 12·010(3) Å, β 105·35(3)°, Z = 8, R 0·046 for No 1380. Cs(2-np).½H2O is monoclinic, P21/n, a 7·648(3), b 26·19(1), c 8·713(6) Å, β 111·75(2)°, Z = 8, R 0·061 for No 2347. All compounds except the lithium derivative are two-dimensional polymeric sheets in which the aromatic rings project to either side of a core of metal atoms coordinated by a web of 2-nitrophenoxide oxygen atoms in various bridging functionalities. The lithium compound is a novel ‘stair’ polymer with two crystallographically independent lithium atoms at successive independent Li–O crossbars, the oxygen atoms of which are phenoxide-Oof each of the two independent ligands. The lithium atoms are alternately four- and five-coordinate, the fourth coordination site of the first being occupied by the water molecule oxygen atom, while the fourth and fifth sites of the second are occupied by the cis-2-nitro oxygen atoms of the two ligands
14
Miesbach, Wolfgang, Karina Meijer, Michiel Coppens, Peter Kampmann, Dr Klamroth, Roger Schutgens, Giancarlo Castaman et al. "Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B". Blood 134, Supplement_1 (13 de novembro de 2019): 2059. http://dx.doi.org/10.1182/blood-2019-122535.
Texto completo da fonteResumo:
Background: The aim of gene therapy is to provide long-term therapeutic effect from a single administration, yet information on response durability is currently limited. AMT-060 is an adeno-associated virus serotype 5 (AAV5) vector with a codon-optimized wildtype human factor IX (FIX) gene and liver-specific promoter. AMT-060 is being analyzed in an ongoing study of 10 participants with severe/moderate-severe hemophilia B (Phase 1/2 study, NCT02396342). Aim: To describe efficacy and safety outcomes from a planned interim analysis at up to 4-years post-AMT-060. Methods: Adult males with FIX activity ≤2% and a severe bleeding phenotype received a single intravenous infusion of AMT-060 (5x1012gc/kg, Cohort 1, n=5) or (2×1013 gc/kg, Cohort 2, n=5). Assessments included FIX activity, FIX replacement use, annualized bleeding rate (ABR), treatment-related adverse events (TRAE), immunological and inflammatory biomarkers up to 4 years (Cohort 1) and 3.5 years (Cohort 2). Results: As of 8 May 2019, for Cohort 1 the mean yearly FIX activity (annualized to 4 years) was 6.0 as compared to 4.4% in the first year, 6.8% in the second year and 7.3% in the third year. Mean yearly FIX activity for Cohort 2 at 3 years was 7.9% as compared to 7.1% in the first year and 8.4% in the second year. Factor IX activity for each patient over the length of follow up is shown in Figure 1. Eight of 9 participants using prophylaxis at baseline were able to discontinue use. During the last 12 months of observation, the mean annualized bleed rate (ABR) was 1.7 for Cohort 1 and 0.7 for Cohort 2. Respectively, these represent a reduction in mean ABR to the year prior to treatment of 88% and 83%. During this same period the consumption of FIX replacement therapy declined 93% and 96% relative to pre-treatment respectively for Cohort 1 and Cohort 2. No participants developed FIX inhibitors or signs of sustained AAV5 capsid-specific T-cell activation. TRAE were mainly reported in the first 3.5-months after treatment, including three participants who experienced transient mild elevations in alanine aminotransferase as previously described. One new TRAE (joint swelling post-exercise) was observed during the last 12 months of observation post-treatment. Updated data, up to 4-years of observation, will be presented for the first time. Conclusions: Long-term stable endogenous FIX activity and reductions in ABR and FIX replacement use were observed following a single treatment with AMT-060. There were no additional safety concerns with longer term follow-up. These findings support the ongoing Phase III study of the enhanced construct, AMT-061, which encodes the highly active Padua FIX variant. Figure 1 Disclosures Miesbach: Bayer, BioMarin, CSL Behring, Chugai, Freeline, Novo Nordisk, Octapharma, Pfizer, Roche, Takeda/Shire, UniQure: Consultancy; Bayer, Novo Nordisk, Octapharma, Pfizer, Takeda/Shire: Research Funding; Bayer, Chugai, Novo Nordisk, Octapharma, Pfizer, Takeda/Shire, UniQure: Speakers Bureau. Meijer:Pfizer, Sanquin, Uniqure: Research Funding; Uniqure, BMS, Aspen, Boehringer Ingelheim, Sanquin, Bayer: Consultancy, Honoraria; Sanquin: Research Funding; Bayer: Research Funding. Coppens:Pfizer: Honoraria; Portola Pharmaceuticals, Inc: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Uniqure: Research Funding; Boehringer Ingelheim: Research Funding; Sanquin Blood Supply: Research Funding; Bayer: Honoraria, Research Funding; CSL Behring: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria. Kampmann:Uniqure BV: Research Funding. Klamroth:Bayer, Biomarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, SOBI, Takeda: Consultancy; Bayer, Novo Nordisk, SOBI: Research Funding. Schutgens:Baxalta Shire, Novo Nordisk, Bayer, CSL Behring, Pfizer, UniQure BV: Research Funding. Castaman:Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; CSL Behring: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda (SHIRE): Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kedrion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Werfen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Research Funding; Uniqure: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Seifried:Medac: Other: BSD owns IP and is contract manufacturer; Uniqure BV: Research Funding. Schwaeble:Uniqure BV: Research Funding. Bönig:Celgene, Novartis, Sandoz Hexal: Consultancy; Kiadis Pharma: Other: Contract manufacturing of ATIR101; Sandoz Hexal, Uniqure: Research Funding; Miletenyi: Speakers Bureau. Sawyer:Uniqure BV: Employment. Leebeek:CSL Behring: Research Funding; UniQure: Consultancy; Shire/Takeda: Research Funding; Novo Nordisk: Consultancy; Sobi: Other: Travel grant; Shire/Takeda: Consultancy.
15
Singh, Mohita, Nath Zungsontiporn, Aslan Turer, Darren Tsang, Austin Deets Ellen Kornkven, Lisa R. Salberg e Mark S. Link. "B-PO02-060 HEALTH RELATED QUALITY OF LIFE IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR". Heart Rhythm 18, n.º 8 (agosto de 2021): S120. http://dx.doi.org/10.1016/j.hrthm.2021.06.316.
Texto completo da fonte
16
Perinetti, Giuseppe. "Temporomandibular Disorders Do Not Correlate with Detectable Alterations in Body Posture". Journal of Contemporary Dental Practice 8, n.º 5 (2007): 60–67. http://dx.doi.org/10.5005/jcdp-8-5-60.
Texto completo da fonteResumo:
Abstract Aim This study aimed to determine if temporomandibular disorders (TMD) correlate with alterations in body posture detectable through posturography. Methods and Materials Thirty-five asymptomatic subjects and 35 TMD patients (34 males and 36 females; mean age, 27.7±8.6 years) constituted the matched control and TMD groups, respectively. Posturography was performed under four different experimental conditions: (a) eyes open with mandibular rest position (Eyes Open RP); (b) eyes open with dental occlusion (Eyes Open DO); (c) eyes closed with mandibular rest position (Eyes Closed RP); and (d) eyes closed with dental occlusion (Eyes Closed DO). The X, Y, and absolute centre of pressure displacements from the projection of a theoretical barycentre and the sway area, sway length, and sway velocity were recorded as static and dynamic posturographic parameters, respectively. Results Generally, no differences were found in any of these parameters between the groups and between the RP and DO within either Eyes Open/Closed conditions. The only differences were found under Eyes Closed as compared to Eyes Open, irrespective of the RP/DO conditions for dynamic and not for static posturographic parameters. Conclusion This study failed to show detectable alterations in body posture in TMD patients. Citation Perinetti G. Temporomandibular Disorders Do Not Correlate with Detectable Alterations in Body Posture. J Contemp Dent Pract 2007 July;(8)5:060-067.
17
Garg, Varun, Fadi Abou Obeid, Venkatesh Ravi, Muhammad Talha Ayub, Timothy R. Larsen, Jeremiah Wasserlauf, Henry D. Huang, Kousik Krishnan, Richard G. Trohman e Parikshit S. Sharma. "B-PO03-060 THE EFFECT OF HIS BUNDLE PACING LEAD THRESHOLDS AT IMPLANT ON LONG TERM LEAD PERFORMANCE". Heart Rhythm 18, n.º 8 (agosto de 2021): S212—S213. http://dx.doi.org/10.1016/j.hrthm.2021.06.535.
Texto completo da fonte
18
Anceau, A. "Sudoite in some Visean (Lower Carboniferous) K-bentonites from Belgium". Clay Minerals 27, n.º 3 (setembro de 1992): 283–92. http://dx.doi.org/10.1180/claymin.1992.027.3.02.
Texto completo da fonteResumo:
AbstractSudoite occurs as a cryptocrystalline clay in some Visean K-bentonites from Belgium. Usually associated with illite-smectite mixed-layers, this chlorite has been found locally as a monomineralic clay component of a K-bentonite bed. The mineral has a composition close to (Al3Mg2)(Si3Al)O10(OH)8. The cell parameters have been calculated from the diffractogram using the space group C2/m (a = 5·228, b = 9·056, c = 14·326 Å, β = 97°00′, d(060) = 1·509 Å). The polytype corresponds to a IIb structure. Some hypotheses are proposed for the origin of this chlorite. The coexistence of sudoite and pyrite could explain why the chlorite present in Visean K-bentonites is not a Fe-rich species typical of diagenetic conditions, but a Fe-poor one.
19
Zwaan, P. C., C. E. S. Arps e E. de Grave. "Vochtenite, (Fe2+,Mg)Fe3+[UO2/PO4]4(OH). 12–13 H2O, a new uranyl phosphate mineral from Wheal Basset, Redruth, Cornwall, England". Mineralogical Magazine 53, n.º 372 (setembro de 1989): 473–78. http://dx.doi.org/10.1180/minmag.1989.053.372.07.
Texto completo da fonteResumo:
AbstractVochtenite, a new mineral from the Basset Mine, southeast of Camborne in Cornwall, England, is a ferrous-ferric magnesium-bearing hydroxy uranyl phosphate mineral. It is monoclinic with a = 12.606, b = 19.990, c = 9.990 Å, β = 102.31° Z = 3; the ideal formula is:The strongest lines in the X-ray powder diffraction pattern are: 9.998(100)(020), 4.999(30)(040), 4.892(45)(002), 3.475(70)(311), 3.333(50)(060), 3.087(40)(232), and . Vochtenite is brown in colour with a bronzy lustre and is non-fluorescent. Mohs hardness is 2.5 and the density (calc.) = 3.663 g/cm3. There is a prominent (010) cleavage. Vochtenite is optical biaxial negative, 2V (calc.) = 89(3)° its dispersion is indiscernible. Refractive indices are α = 1.575(2), β = 1.589(2), γ = 1.603(2), and the pleochroism is very weak. Orientation X(α)∥b is perpendicular to (010) and Z(γ)∧c is small. The mineral occurs as subparallel (0.5–1.0 mm) crystal aggregates with a pseudo-quadratic outline. The mineral is named vochtenite after Prof. Dr. Ing. R. F. C. Vochten of the State University of Antwerpen, Belgium.
20
Fernandes-Acioli, N. A. N., R. C. Pereira-Carvalho, R. S. Fontenele, C. Lacorte, S. G. Ribeiro, M. E. N. Fonseca e L. S. Boiteux. "First Report of Sida micrantha mosaic virus in Phaseolus vulgaris in Brazil". Plant Disease 95, n.º 9 (setembro de 2011): 1196. http://dx.doi.org/10.1094/pdis-05-10-0343.
Texto completo da fonteResumo:
Snap and common beans (Phaseolus vulgaris L.) are severely affected by Bean golden mosaic virus (BGMV) infection, so far the only begomovirus reported on these crops in Brazil (1). Samples of snap and common beans colonized by the whitefly Bemisia tabaci biotype B and displaying golden mosaic, chlorotic spots, and leaf distortion were collected in three production regions in Goiás State (Goianápolis, Luziânia, and Itaberaí) between 2003 and 2007. Total DNA extracted from leaf samples was used as template in PCR assays using universal primers targeting conserved regions of the DNA-A and DNA-B genomes (3). Begomovirus-specific amplicons were observed only with DNA template from symptomatic plants. Two single amplicons were observed for both genomic segments, indicating the presence of bipartite species in all samples. Sequence analysis of four isolates (named as GO-176, GO-260, GO-354, and GO-368) obtained from common bean samples indicated identity levels of approximately 95% with the DNA-A segment of BGMV (GenBank Accession No. FJ665283). However, the complete DNA-A sequence (GenBank Accession No. HM357459.1) of the GO-060 isolate (from a symptomatic snap bean plant collected in Goianápolis) displayed 76% identity with BGMV (GenBank Accession No. FJ665283) and 95% identity with the DNA-A of a Sida micrantha mosaic virus (SimMV) isolate (GenBank Accession No. EU908733.1) reported to be infecting okra (Abelmoschus esculentus L.) and 94.8% with a SimMV isolate reported to be infecting soybean (GenBank Accession No. FJ686693) in Brazil (2). Koch's postulates were fulfilled for the isolate GO-060 by inoculating a set of soybean and bean accessions via a biolistic approach. The ratio of positive PCR amplicons per total of inoculated plants were 15 of 16 for snap bean cv. Trepador, 9 of 10 for snap bean cv. Fartura, 18 of 24 for common bean cv. Olate Pinto, and 19 of 25 for common bean cv. Carioca. The isolate was also able to infect eight of nine soybean ‘Doko’ plants. Sequence analysis using symptomatic leaf samples (15 days after inoculation) confirmed SimMV as the causal agent. To our knowledge, this is the first report of a SimMV isolate infecting P. vulgaris. This virus is apparently fast expanding its host range from Malvaceae to Solanaceae species and leguminous hosts after the introduction of B. tabaci biotype B (2). More extensive surveys are necessary to access the current epidemiological importance of SimMV in both snap and common beans in Brazil. References: (1) J.C. Faria and D. P. Maxwell. Phytopathology 89:262, 1999. (2) F. R. Fernandes et al. Arch. Virol. 154:1567, 2009. (3) M. R. Rojas et al. Plant Dis. 77:340, 1993.
21
Bowmaker, Graham A., Frances M. M. Hannaway, Peter C. Junk, Aaron M. Lee, Brian W. Skelton e Allan H. White. "Synthetic, Structural and Vibrational Spectroscopic Studies in Bismuth(III) Halide/N,N′-Aromatic Bidentate Base Systems. V Bismuth(III) Halide/N,N′-Bidentate Ligand (1 : 2) Systems". Australian Journal of Chemistry 51, n.º 4 (1998): 331. http://dx.doi.org/10.1071/c97040.
Texto completo da fonteResumo:
Syntheses and room-temperature single-crystal X-ray determinations are recorded for a number of adducts of BiX3/N,N′-bidentate 1 : 2 stoichiometry (N,N′-bidentate = 2,2′-bipyridine (bpy) or 1,10-phenanthroline (phen)). BiX3/bpy (1 : 2), X = Br, I, are isomorphous, monoclinic, P21/c, a ≈ 7·5, b ≈ 31, c ≈ 10·3 Å, β ≈ 113°, Z = 4; conventional R on |F| were 0·058, 0·055 for No 1744, 2068 independent ‘observed’ (I > 3σ(I)) reflections. BiCl3/phen (1 : 2) is monoclinic, P21/C, a 9·675(3), b 31·845(7), c 7·756(2) Å, β 109·94(2), Z = 4, R 0·071 for No 2537, while BiBr3/phen (1 : 2), also monoclinic, P21/c, has a 17·590(5), b 8·812(2), c 17·537(7) Å, β 117·58(3)°, Z = 4; R 0·083 for No 890. BiX3/phen (1 : 2).S, X/S = Br/MeCN, I/CH2Cl2, are isomorphous, orthorhombic, Pna21, a ≈ 20·7, b ≈ 14·2, c ≈ 8·9 Å, Z = 4, R 0·060, 0·046 for No 1553, 2423 respectively. All complexes are mononuclear with seven-coordinate (N2)2BiX3 bismuth environments. Bands in the far-infrared spectra due to the v(BiX) vibrations in [(phen)2BiCl3] and [(bpy)2BiX3] (X = Br, I) are assigned and discussed in relation to the structures of the complexes.
22
Semenova, Lioubov I., e Allan H. White. "Structural Systematics of Rare Earth Complexes. XIX (Hydrated) 1 : 2 Mononuclear Adducts of Lanthanoid(III) Chlorides with 2,2′-Bipyridine and 1,10-Phenanthroline". Australian Journal of Chemistry 52, n.º 6 (1999): 571. http://dx.doi.org/10.1071/ch98052.
Texto completo da fonteResumo:
Room-temperature single-crystal X-ray structure determinations are recorded for a number of adducts of hydrated lanthanoid(III) trichlorides with 2,2′-bipyridine (‘bpy’) and 1,10-phenanthroline (‘phen’), crystallized from water, methanol or ethanol solutions, containing mononuclear arrays with 1 : 2 Ln/bpy or phen stoichiometry. LaCl3/phen/H2O(1 : 3 : 9), [(phen)2La(OH2)5]Cl3.phen.4H2O, although of overall 1 : 3 LaCl3/phen stoichiometry, has a lattice phen; it is orthorhombic, Pnna, a 19·947(7), b 16·457(5), c 12·213(2) Å, Z = 4; conventional R on |F| was 0·030 for No 2567 ‘observed’ (I >3σ(I)) diffractometer reflections. LaCl3/phen/H2O/MeOH (1 : 2 : 6 : 1), [(phen)2La(OH2)5]Cl3.H2O.MeOH, is triclinic, P 1, a 19·060(3), b 9·252(3), c 8·994(3) Å, α 69·33(3), β 86·81(2), γ 89·66(2)°, Z = 2, R 0·037 for No 5452. LaCl3/bpy/H2O (1 : 2 : 6), [(bpy)2La(OH2)4Cl]Cl2.2H2O, is monoclinic, P 21/c, a 19·389(3), b 9·071(1), c 16·873(2) Å, β 114·10(1)°, Z = 4, R 0·029 for No 4699. All three of these complexes have a nine-coordinate [(N,N′-bidentate)2La(unidentate)5] coordination environment with quasi-2 symmetry; that of the remaining compounds following is eight-coordinate [(N,N′-bidentate)2Ln(unidentate)4]. LuCl3/phen/H2O (1 : 2 : 6), [(phen)2Lu(OH2)4]Cl3.2H2O, is monoclinic, C 2/c, a 11·045(7), b 17·660(6), c 14·474(9) Å, β 92·82(5)°, Z = 4, R 0·042 for No 1695, the Lu lying on a crystallographic 2 -axis. Crystals of LnCl3/phen/H2O(1 : 2 : 4), [(phen)2Ln(OH2)3Cl]Cl2.H2O (Ln = Dy, Er, Y), are triclinic, P 1, a≈ 12·6, b ≈ 10·5, c ≈ 10·4 Å, α ≈ 93·3, β ≈ 109·3, γ ≈ 96·8°, Z = 2, R 0·030, 0·040, 0·052 for No 4221, 5100, 2690 respectively. PrCl3/bpy/H2O/EtOH (1 : 2 : 1 : 0·5), [(bpy)2Pr(OH2)Cl3].½EtOH, is triclinic, P 1, a 13·331(3), b 10·734(2), c 9·758(2) Å, α 63·67(2), β 78·99(2), γ 71·24(2)°, Z = 2, R 0·033 for No 4596, while [(bpy)2Pr(OH2)2Cl2]Cl is monoclinic, C 2/c, a 15·921(15), b 11·314(8), c 14·114(8) Å, β 116·70(6)°, Z = 4, R 0·041 for No 2269. ErCl3/bpy/H2O(1 : 2 : 2 (also)), [(bpy)2Er(OH2)2Cl2]Cl, is cubic, I 23, a 26·032(4) Å, Z = 24, R 0·066 for No 1644. Crystals of LnCl3/phen/H2O/MeOH (1 : 2 : 1 : 1), [(phen)2Ln(OH2)Cl3].MeOH (Ln = La, Pr, Nd, Eu), are monoclinic, P 21/a, a ≈ 13·2, b ≈ 10·7, c ≈ 18·5 Å, β ≈ 102·1°, Z = 4, R 0·054, 0·032, 0·040, 0·054 for No 2872, 4792, 3179, 2847 respectively. LnCl3/bpy/H2O/EtOH (1 : 2 : 1 : 1), [(bpy)2Ln(OH2)Cl3].EtOH (Ln = Nd, Eu), are triclinic, P 1, a ≈ 11·3, b ≈ 10·9, c ≈ 10·4 Å, α ≈ 75·5, β ≈ 89·8, γ ≈ 78·0°, Z = 2, R 0·044, 0·056 for No 4979, 3596 respectively. LaCl3/bpy/EtOH (1 : 2 : 0·5) is binuclear [(bpy)2Cl2La(µ-Cl)2LaCl2(bpy)2].EtOH, monoclinic, P 21/c, a 9·6878(2), b 17·5696(3), c 16·1341(2) Å, β 123·10(1)°, Z = 2, R 0·033 for No 4256. A totally unsolvated array is found for YbCl3/bpy (1 : 2), [(bpy)2YbCl3], monoclinic, P 21/c, a 15·065(8), b 8·598(4), c 16·92(1) Å, β 112·46(5)°, Z = 4, R 0·032 for No 3548, in which, alone, the metal atom is seven-coordinate.
23
Weber, Jeffrey S., Hao Tang, Lauren Hippeli, Max Qian, Megan Wind-Rotolo, James M. G. Larkin, Jedd D. Wolchok et al. "Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 100. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.100.
Texto completo da fonteResumo:
100 Background: Acute phase reactants including C-reactive protein (CRP), and chronic inflammatory proteins including IL-6, which induces production of CRP from the liver, have been associated with a poor outcome in a variety of cancers. Methods: Sera from the CheckMate 064, 066 and 067 studies were assessed at baseline and on treatment for levels of IL-6 and CRP by Luminex. Associations between IL-6 and/or CRP levels and response or survival were determined. Purified endotoxin- and azide-free CRP was also tested for its immune effects in vitro using human T cells. Results: In patients receiving sequential nivolumab then ipilimumab in CheckMate 064 (cohort A), baseline serum IL-6 was associated with response (p = 0.03); serum IL-6 at week 12 after nivolumab alone (cohort A) or ipilimumab alone (cohort B), was also associated with response (p = 0.004 and 0.006, respectively). Baseline IL-6 above the median was associated with shorter survival in cohort A (p = 0.003) and cohort B (p = 0.0001). Serum CRP above the median was associated with shorter survival in cohort A (p = 0.001). Baseline IL-6 and CRP in cohort A were associated with one another, rho = 0.71 and p < 0.0001 In the randomized CheckMate 067 study, higher baseline serum CRP above the median was associated with shorter survival for ipilimumab, nivolumab or the combination with p < 0.0001, p < 0.11, and p = 0.0034, respectively. In the randomized CheckMate 066 study, higher baseline serum CRP was associated with shorter survival for nivolumab or dacarbazine (p = 0.131 and P < 0.0001 respectively). CRP suppressed T cell immunity and function, and levels above 10 micrograms/mL suppressed T cell proliferation (p = 0.005) and altered T cell signaling as well as calcium flux (p = 0.01), suggesting that CRP affected the earliest steps in T cell signaling and activation. Conclusions: High levels of CRP and IL-6 at baseline were associated with a poor response and shorter survival after nivolumab alone, and CRP with ipilimumab alone or the combination of both drugs. High levels of CRP were also associated with shorter overall survival in the randomized CheckMate 066 study of chemotherapy compared to nivolumab. CRP and IL-6 are prognostic factors for checkpoint inhibition.
24
Amirpur, Katajun. "In the Rose Garden of the Martyrs: A Memoir of Iran, Christopher de Bellaigue, New York: HarperCollins, 2005, ISBN 0–060–93536–7, 283 pp." Iranian Studies 41, n.º 3 (junho de 2008): 417–19. http://dx.doi.org/10.1017/s0021086200031030.
Texto completo da fonte
25
Frossard, Alexandra, Maria Tereza Weitzel Dias Carneiro, Eduardo Lázaro de Faria da Silva, Claudio Barberine Camargo Filho e João Luiz Rossi Júnior. "Concentração de elementos traços em serpentes do litoral e da região serrana do Espírito Santo". Pesquisa Veterinária Brasileira 37, n.º 10 (outubro de 2017): 1146–52. http://dx.doi.org/10.1590/s0100-736x2017001000017.
Texto completo da fonteResumo:
RESUMO: Os elementos químicos, em sua maioria, encontram-se em ciclos bioquímicos e geoquímicos fechados e em concentrações que não causam efeitos nocivos aos organismos. Contudo, ações antrópicas aceleradas promovem alterações ambientais, como o aumento no aporte de contaminantes. Com essas informações, o presente trabalho buscou caracterizar a presença aos elementos traços em duas espécies de serpentes comuns na região sudeste, Boa constrictor e Bothrops jararaca. Os exemplares de B. constrictor (n=18) foram provenientes de atropelamentos ocorridos no trecho da Rodovia ES-060 do Km 0 ao Km 67,5. Os exemplares de B. jararaca (n=18) foram capturados por fazendeiros na zona rural da região serrana do Espírito Santo. Foram analisados 1 grama de fragmento de rim, de espécimes necropsiados. Os rins coletados foram digeridos com mistura ácida (HNO3;HCl; 1:1) a 300oC, 40min e a quantificação de microelementos (Cd, Co, Cr, Cu, Fe, Mn, Ni, Pb e Zn) foi realizada por espectrometria de emissão óptica com plasma indutivamente acoplado (ICP OES). Não foram observadas diferenças significativas entre machos e fêmeas, exceto para Cromo nas B. constrictor (p=0,03), com média de 1,6595 nas concentrações de Cr nas fêmeas e 0,2896 em machos. Contudo, quando foram comparadas as diferentes espécies de serpentes, diferentes concentrações foram encontradas, para todos os elementos determinados, com destaque para o Ferro com uma concentração de 106,2mg/g em B. constrictor e 120,3mg/g em B. jararaca, provavelmente por esses animais virem de áreas próximas à portos de minério de ferro. A concentração de Zinco em B. constrictor foi de 1261,8mg/g e em B. jararaca foi de 28,4mg/g. O presente estudo indica que as serpentes analisadas, que habitam as regiões da Grande Vitória e serrana do Espírito Santo apresentam elevadas concentrações dos microelementos Zn e Fe.
26
Tian, Wei, JinHong Cai e XueXiang Liu. "MICA genetic polymorphism and HLA-A,C,B,MICA and DRB1 haplotypic variation in a southern Chinese Han population: Identification of two new MICA alleles, MICA*060 and MICA*062". Human Immunology 72, n.º 6 (junho de 2011): 510–15. http://dx.doi.org/10.1016/j.humimm.2011.03.006.
Texto completo da fonte
27
Donati, Donato, Stefano Roelens, Riccardo Torriti e Giovanni Valle. "Structure and Binding Properties of Four New Oligomeric Cyclophane Esters: 1,4-Xylylene 1,4-Phenylene Diacetates and Dipropionates". Australian Journal of Chemistry 51, n.º 5 (1998): 361. http://dx.doi.org/10.1071/c97215.
Texto completo da fonteResumo:
The X-ray crystal structure determinations of four new oligomeric cyclophane esters are reported. They are: (3a) monomeric 1,4-xylylene (1,4-phenylene)diacetate, P21/n (No. 14), a 5·959(5), b 15·795(5), c 8·094(5) Å, β 108·060(5)°, V 724·3(8) Å3 , Z 2, R1(2σ) 0·0522, wR2 0·125; (3b) monomeric 1,4-xylylene (1,4-phenylene)dipropionate, P21/c (No. 14), a 5·878(1), b 14·642(2), c 18·909(2) Å, β 96·00(10)°, V 1618·5(4) Å3 , Z 4, R1(2σ) 0·053, wR2 0·165; (3c) dimeric 1,4-xylylene (1,4-phenylene)diacetate, P-1 (No. 2), a 14·633(2), b 17·529(2), c 5·736(1) Å, α 98·30(10), β 90·60(10), γ 95·40(10)°, V 1449·0(4) Å3, Z 2, R1(2σ) 0·057, wR2 0·158; (3d) dimeric 1,4-xylylene (1,4-phenylene)dipropionate, P21/a (No. 14), a 8·145(1), b 11·379(2), c 17·401(2) Å, β 101·40(10)°, V 1580·9(4) Å3, Z 4, R1(2σ) 0·034, wR2 0·095. Monomeric cyclophanes (3a,b) exhibit a well defined cleft, while dimeric (3c,d) adopt a flat conformation devoid of cavities. Binding properties were determined by 1H n.m.r. titrations in CDCl3 at T = 296 K. Complexation experiments with quaternary ammonium salts revealed that host (3c) possesses appreciable binding ability toward N-methylpyridinium (–ΔG° = 5·9 kJ mol-1), tetramethylammonium (–ΔG° = 8·8 kJ mol-1) and acetylcholine (–ΔG° = 7·5 kJ mol-1) cations, despite its lack of a preorganized cavity.
28
Wadhwani, Lalit, Ahmed Mohamed Abdelhalim Selim, Alexander Kushnir, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, Scott A. Bernstein et al. "B-PO05-060 TIME TO DIAGNOSIS OF COMPLICATIONS FOR ASSESSMENT OF SAFETY OF EARLY DISCHARGE AFTER CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICE IMPLANT". Heart Rhythm 18, n.º 8 (agosto de 2021): S396. http://dx.doi.org/10.1016/j.hrthm.2021.06.980.
Texto completo da fonte
29
Braterman, Paul S. "Layered Double Hydroxides: Present and Future, edited by Vicente Rives. Nova Science Publishers, New York, (2001), ix + 439 pages. [ISBN: 1-59033-060-9]. Price $89." Clays and Clay Minerals 51, n.º 2 (abril de 2003): 226–27. http://dx.doi.org/10.1017/s000986040002471x.
Texto completo da fonte
30
Rordorf, Roberto, Silvana De Bonis, Antonio D’Onofrio, Stefano Viani, Gianluca Savarese, Pietro Francia, Eduardo Celentano et al. "B-PO04-060 DEVICE-RELATED DISTRESS, BODY IMAGE CONCERNS, RETURN TO FUNCTION AND POSITIVE APPRAISAL IN PATIENTS WITH SUBCUTANEOUS VERSUS TRANSVENOUS DEFIBRILLATOR". Heart Rhythm 18, n.º 8 (agosto de 2021): S303. http://dx.doi.org/10.1016/j.hrthm.2021.06.756.
Texto completo da fonte
31
Nezu, Akihiro, Mst Tahmnia Akter e Akihiko Tanimura. "Pharmacological analysis of salivary secretion mechanisms using rats with different strains of Aquaporin 5 levels." Proceedings for Annual Meeting of The Japanese Pharmacological Society 96 (2022): 1—B—P—060. http://dx.doi.org/10.1254/jpssuppl.96.0_1-b-p-060.
Texto completo da fonte
32
Miura, Ayako, Fumiyuki Sanematsu e Ryu Takeya. "Role of ERM proteins in the regulation of actin cytoskeleton in migrating alveolar macrophage." Proceedings for Annual Meeting of The Japanese Pharmacological Society 97 (2023): 1—B—P—060. http://dx.doi.org/10.1254/jpssuppl.97.0_1-b-p-060.
Texto completo da fonte
33
Shimizu, Kahori, Moe Ono, Takenari Mikamoto, Yuya Urayama, Hiroki Nakanishi, Shotaro Michinaga, Sena Yoshida et al. "リゾリン脂質アシル転移酵素LPLAT10/LPCAT4/LPEAT2の肝臓特異的な高発現は、グルコース依存性インスリン分泌を促進する". Proceedings for Annual Meeting of The Japanese Pharmacological Society 97 (2023): 2—B—P—060. http://dx.doi.org/10.1254/jpssuppl.97.0_2-b-p-060.
Texto completo da fonte
34
Kiyoi, Takeshi, Li Liu, Qiang He, Shijie Zheng, Hitomi Nakazawa, Junsuke Uwada e Takayoshi Masuoka. "Influence of anticancer drug S-1 on ocular surface with histological alterations of corneal nerve in rat". Proceedings for Annual Meeting of The Japanese Pharmacological Society 97 (2023): 3—B—P—060. http://dx.doi.org/10.1254/jpssuppl.97.0_3-b-p-060.
Texto completo da fonte
35
Jung, Haewon, Seung Pyo Hong e Jin Bae Lee. "TCTAP A-060 The LDL-C/Apo B Ratio Predicts Coronary Artery Disease in Patients Younger Than 65 Years With Low LDL-C". Journal of the American College of Cardiology 79, n.º 15 (abril de 2022): S37. http://dx.doi.org/10.1016/j.jacc.2022.03.084.
Texto completo da fonte
36
Zhao, Jingxuan, Zhiyuan Zheng, Xuesong Han, Amy J. Davidoff, Matthew P. Banegas, Ashish Rai, Ahmedin Jemal e K. Robin Yabroff. "Cancer history, health insurance coverage, and cost-related medication nonadherence and medication cost-coping strategies in the United States." Journal of Clinical Oncology 36, n.º 30_suppl (20 de outubro de 2018): 68. http://dx.doi.org/10.1200/jco.2018.36.30_suppl.68.
Texto completo da fonteResumo:
68 Background: Policy makers, health care providers and patients are increasingly concerned about rising costs for prescription drugs and cost-related medication non-adherence (CRN). This study aims to evaluate the relationship between cancer history and CRN as well as cost-coping strategies, by health insurance coverage. Methods: We used the National Health Interview Survey data from 2013-2016 to identify adults age 18-64 with (n = 3 599) and without (n = 56 909) a cancer history. Cost-related changes in medication use included a) CRN (skipping, taking less or delaying medication because of cost), and b) cost-coping strategies (requesting lower cost medication or using alternative therapies to save money). Separate multivariable logistic regressions were used to calculate the adjusted percentages of CRN and cost-coping strategies associated with cancer history, stratified by health insurance. Results: Cancer survivors reported higher percentages of CRN (14.5% vs. 12.1%, P < .001) and were slightly more likely to report using cost-coping strategies (24.4% vs. 22.8%, P = .060) compared with adults without a cancer history. The magnitude of differences in CRN by cancer history varied by insurance type (any private 10.2% vs. 8.6%, P = .034; public only 17.9% vs. 14.2%, P = .010; uninsured 41.0% vs. 33.2%, P = .064). Among the privately insured, the difference in CRN by cancer history was greatest among those enrolled in high deductible health plans (HDHP) without health saving accounts (HSA) (16.9% vs. 10.9%, P = .002). Regardless of cancer history, CRN and use of cost-coping strategies were highest for those uninsured, enrolled in HDHP and without HSA, and without prescription drugs coverage under their health plan (all P < .001). Conclusions: Cancer survivors are prone to CRN and more likely to use cost-coping strategies to minimize financial hardship. Expanding options for health insurance coverage and use of HSA, and prescription drug coverage may be effective strategies to address CRN.
37
Matías-González, Yatzmeli, Astrid Sánchez-Galarza, Ernesto Rosario-Hernández, Idhaliz Flores-Caldera e Eliut Rivera-Segarra. "Stigma and social support and their impact on quality of life and self-esteem among women with endometriosis in Latin-America and the Caribbean". PLOS Global Public Health 2, n.º 12 (2 de dezembro de 2022): e0001329. http://dx.doi.org/10.1371/journal.pgph.0001329.
Texto completo da fonteResumo:
Endometriosis is a complex disease affecting approximately 5–10% individuals worldwide. Prevalence rates in Latin-America and the Caribbean are largely unknown, with published data only from Puerto Rico and Chile. Pain associated with endometriosis negatively affects patients’ health and quality of life. However, there is a need to better understand the role played by psychosocial variables such as stigma and social support in diverse cultural contexts. The purpose of this study was to examine the mediating role of endometriosis related stigma (endo-stigma) and the moderating role of social support on the endometriosis QoL and self-esteem among women with endometriosis from Latin America and the Caribbean. A cross-sectional design with online survey techniques was implemented. A total of 169 self-identified cisgender women with endometriosis from 14 Latin-American and Caribbean countries participated in the study. We used partial least squares structural equation modeling (PLS-SEM) to examine the study’s hypotheses. Incapacitating pain was positively and significantly related to endometriosis QoL as measured by the EHP-5 (b = .266, p < .01). Endo-stigma was positively and significantly related to endometriosis QoL (b = .340, p< .01) and self-esteem (b = .297, p< .01). In addition, endo-stigma mediated the relationship between incapacitating pain and self-esteem (IE = .073, p = .018). Finally, social support moderated the relationship between stigma stress and endometriosis QoL (b = .060, p = .039). Findings suggest stigma could be one of the mechanisms through which the relationship between incapacitating pain and self-esteem among Latin American and Caribbean women with endometriosis could be partially explained. Furthermore, women who scored high in the need for social support and stigma stress also showed worst endometriosis QoL. These results point towards the need to develop tailored interventions targeting these factors in order to foster a better QoL and wellbeing for this population in the context of Latin America and the Caribbean.
38
Zeng, Wanwen, Shengquan Chen, Xuejian Cui, Xiaoyang Chen, Zijing Gao e Rui Jiang. "SilencerDB: a comprehensive database of silencers". Nucleic Acids Research 49, n.º D1 (12 de outubro de 2020): D221—D228. http://dx.doi.org/10.1093/nar/gkaa839.
Texto completo da fonteResumo:
Abstract Gene regulatory elements, including promoters, enhancers, silencers, etc., control transcriptional programs in a spatiotemporal manner. Though these elements are known to be able to induce either positive or negative transcriptional control, the community has been mostly studying enhancers which amplify transcription initiation, with less emphasis given to silencers which repress gene expression. To facilitate the study of silencers and the investigation of their potential roles in transcriptional control, we developed SilencerDB (http://health.tsinghua.edu.cn/silencerdb/), a comprehensive database of silencers by manually curating silencers from 2300 published articles. The current version, SilencerDB 1.0, contains (1) 33 060 validated silencers from experimental methods, and (ii) 5 045 547 predicted silencers from state-of-the-art machine learning methods. The functionality of SilencerDB includes (a) standardized categorization of silencers in a tree-structured class hierarchy based on species, organ, tissue and cell line and (b) comprehensive annotations of silencers with the nearest gene and potential regulatory genes. SilencerDB, to the best of our knowledge, is the first comprehensive database at this scale dedicated to silencers, with reliable annotations and user-friendly interactive database features. We believe this database has the potential to enable advanced understanding of silencers in regulatory mechanisms and to empower researchers to devise diverse applications of silencers in disease development.
39
Miesbach, W., M. Recht, N. Key, R. Guillen-Gonzalez, K. Sivamurthy, P. Monahan e S. Pipe. "OC 52.1 Assessing the Safety Profile of AMT-060 and Etranacogene Dezaparvovec Gene Therapies Across Clinical Trials in People with Severe/Moderately Severe Hemophilia B". Research and Practice in Thrombosis and Haemostasis 7 (outubro de 2023): 100456. http://dx.doi.org/10.1016/j.rpth.2023.100456.
Texto completo da fonte
40
Girard, Hélène, Wanda Bosshard, Hélène Krief e Christophe J. Büla. "Effectiveness of Information Sessions About COVID-19 Vaccines in Healthcare Professionals Working in Geriatrics". Gerontology and Geriatric Medicine 8 (abril de 2022): 233372142211152. http://dx.doi.org/10.1177/23337214221115235.
Texto completo da fonteResumo:
Objectives: To determine change in (a) perceived knowledge about COVID-19 vaccines; (b) level of confidence in transmitting information about vaccines; and (c) intention to get vaccinated; among healthcare professionals (HCP) working in a Swiss academic geriatric department who attended a 30-minute information session about COVID-19 vaccines. Measurements: At the session’s end, a self-administered questionnaire collected information about socio-demographics, personnel, and/or relatives’ experience with COVID-19. In addition, participants were asked to rate their: (a) perceived knowledge about COVID-19 vaccines; (b) level of confidence in transmitting information about COVID-19 vaccines to patients and relatives; and (c) intention to get vaccinated; before and after the session. Results: Overall, 97 (42.2% of all HCPs) participated to 14 sessions and completed the questionnaire. Improvements were observed in knowledge, confidence in providing information, and intention to be vaccinated after the session (all p < .001). Similar improvements were observed in subgroup analyses by gender, age groups, profession (involved in direct care or not), and previous experience with COVID-19 (all p < .010). However, HCP aged 20 to 29 years were less likely to feel completely confident in providing information than those aged 30 to 49 and 50+ years (17.1% vs. 43.2% vs. 44.0%, respectively, p = .031) and to report being very likely to be vaccinated (31.4% vs. 56.8% vs. 56.0%, respectively, p = .060). Conclusions: These information sessions positively influenced HCP knowledge, confidence in providing information, and, to a lesser extent, intention to be vaccinated. Younger HCP reported similar improvements but remained less likely to consider vaccination. Additional efforts are needed to convince these undecided HCP and enhance COVID-19 vaccines uptake.
41
Ge, W. W., H. J. Zhang, J. Y. Wang, M. H. Jiang, S. Q. Sun, D. G. Ran, H. R. Xia e R. I. Boughton. "Thermal properties of monoclinic crystal Er3+:Yb3+:Ca4YO(BO3)3". Journal of Applied Crystallography 40, n.º 1 (12 de janeiro de 2007): 125–32. http://dx.doi.org/10.1107/s0021889806045407.
Texto completo da fonteResumo:
A large Er3+–Yb3+co-doped yttrium calcium oxoborate [Er3+:Yb3+:Ca4YO(BO3)3, abbreviated as Er:Yb:YCOB] single crystal, with dimensions of 2.5 cm in diameter and 9.0 cm in length, has been grown along the crystallographicbaxis by the Czochralski method. X-ray powder diffraction results show that the as-grown Er:Yb:YCOB crystal belongs to the monoclinic system with space groupCm; the unit-cell constants area= 8.085,b= 16.048,c= 3.528 Å and β = 101.11°. The high crystalline quality of the as-grown single crystal was confirmed by high-resolution X-ray diffraction, which showed the full width at half-maximum of the rocking curves to be less than 20 arcseconds on the (060) and (\overline 201) diffraction planes. The measurement and calculation of the symmetrical second-rank tensor for the monoclinic crystal are described in detail in this paper. The principal coefficients of thermal expansion of the as-grown Er:Yb:YCOB crystal are αI= 11.95 × 10−6 K−1, αII= 9.20 × 10−6 K−1and αIII= 18.93 × 10−6 K−1over the temperature range 303.15–873.15 K. The specific heat of the crystal is 725.6 J kg−1 K−1at 328.15 K. The principal thermal conductivity parameters areKI= 2.882 W m−1 K−1,KII= 2.687 W m−1 K−1andKIII= 2.692 W m−1 K−1at 328.15 K.
42
Jones, Peter Blundell. "The Woodland Cemetery: Toward a Spiritual Landscape by Caroline Constant, Byggförlaget, Stockholm1994210 pages 130 b&w illus, ISBN 91-7988-060-6 Price £37.95 (SB)". Architectural Research Quarterly 1, n.º 2 (1995): 94–96. http://dx.doi.org/10.1017/s1359135500002827.
Texto completo da fonte
43
Попова, Надежда, Сергей Новиков, Павел Крживицкий, Людмила Жукова, Петр Криворотько, Анна Артемьева, Алина Валитова et al. "Diagnostic Capabilities of Scintimammography in Detecting Multicentric and Minimal Breast Cancer of Various Molecular Subtypes". Voprosy onkologii 69, n.º 4 (2 de setembro de 2023): 708–14. http://dx.doi.org/10.37469/0507-3758-2023-69-4-708-714.
Texto completo da fonteResumo:
Цель. Определение информативности сцинтимаммографии/молекулярной визуализации (МСГ/МВ) при выявлении минимальных форм (МФ) рака молочной железы (РМЖ), а также установление частоты визуализации мультицентричного (МЦ) опухолевого процесса у больных с различными биологическими подтипами РМЖ. Материалы и методы. В анализ вошли результаты МСГ/МВ 1080 женщин (2 154 молочных желез), обследованных в связи с подозрением на наличие РМЖ. Радионуклидные исследования — МСГ/МВ выполнялись через 15-20 минут после введения в вену одной из стоп 370-740 МБк 99mTc-«MIBI». Верификация изменений в 1 060 случаях осуществлялась с помощью морфологического исследования, в остальных — при динамическом наблюдении. К МФ РМЖ относили все гистологически подтвержденные опухолевые очаги размерами до 10 мм. Сцинтиграфическими признаками МЦ опухолевого процесса считали наличие двух или более очагов, локализованных в разных квадрантах и/или одном квадранте, но на расстоянии не менее 30 мм друг от друга. Результаты. Чувствительность МСГ/МВ в диагностике МФ РМЖ в целом составила 82 %. У больных с различными биологическими подтипами РМЖ чувствительность МСГ/МВ составила 76 % при люминальном А; 80 % и 91 % — при люминальных В «-» и «+» подтипах, 90 % и 100 % — при трижды негативном и HER2 позитивном подтипах соответственно. Показатели чувствительности метода в диагностике минимальных форм трижды негативного и HER2 позитивного РМЖ оказались достоверно выше, чем в диагностике люминальных А и В-подтипов (p = 0,02). Частота визуализации МЦ РМЖ в зависимости от биологических подтипов различалась: при HER2 позитивном - 19 случаев (20,2 %), что достоверно выше (р = 0,006), чем при других молекулярно-биологических подтипах: люминальный A — 25 (10,5 %), люминальный B — 41 (11,4 %), люминальный B+ — 19 (12,6 %), трижды негативный — 18 случаев (10,3 %). Выводы. Определяется достоверное увеличение чувствительности МСГ/МВ при диагностике МФ РМЖ наиболее агрессивных биологических подтипов: 90% - при трижды негативном и 100% - при HER2 позитивном РМЖ. Установлена наиболее высокая частота визуализации МЦ РМЖ у больных с HER2+ подтипом РМЖ (20,2 %).
44
Carey, I., M. Cavers, L. D'Antiga, Y. Ma, S. Bansal, J. Byrne, G. Mieli-Vergani e D. Vergani. "O.060 The outcome of combined antiviral therapy in tolerant children with chronic hepatitis B is associated with emergence of mutations within HBV core gene immunodominant epitopes". Journal of Clinical Virology 36 (janeiro de 2006): S18. http://dx.doi.org/10.1016/s1386-6532(06)80065-x.
Texto completo da fonte
45
Steiger, Nathaniel, Grace Foley, Pierre C. Qian, Clinton J. Thurber, John Whitaker, Parinita A. Dherange, Ahmad Halawa et al. "B-PO01-060 THE DELIVERY PATTERN OF RADIOFREQUENCY APPLICATIONS IN A LEFT ATRIAL-ESOPHAGEAL ABLATION MODEL DEMONSTRATES A HEAT STACK EFFECT: IMPLICATIONS FOR LEFT ATRIAL POSTERIOR WALL ABLATION". Heart Rhythm 18, n.º 8 (agosto de 2021): S75. http://dx.doi.org/10.1016/j.hrthm.2021.06.206.
Texto completo da fonte
46
Morrison, Clare, Patrick Pikacha, Tikai Pitakia e David Boseto. "Herpetofauna, community education and logging on Choiseul Island, Solomon Islands: implications for conservation". Pacific Conservation Biology 13, n.º 4 (2007): 250. http://dx.doi.org/10.1071/pc070250.
Texto completo da fonteResumo:
Biodiversity in the Solomon Islands Is extremely rich, and in the Pacific is second only to Papua New Guinea. Despite this high diversity there are only rough estimates for the biodiversity of most taxa in the Solomon Islands. As part of a terrestrial biodiversity survey, we conducted nocturnal surveys for frogs in a range of habitats from 10?1 060 m on Choiseul Island. This work was carried out between June 2005 and January 2006. In addition to the nocturnal surveys, we also conducted opportunistic diurnal searches for reptiles as well as community environmental education and awareness workshops. Fifteen frog species (65% of all Solomon Island frogs) including all five endemic species, were found during our surveys of Choiseul Island. Most of the species were fairly widespread and abundant, however, four species (Discodeles bufoniformis, Palmatorrapia solomonis, Brachylodes trossulus and B. wolfi) were fairly restricted in their distribution. In addition, we found 20 reptile species during opportunistic surveys (30% of all Solomon Island reptiles Including four endemics). Important habitats on Choiseul Island based on frog species richness and abundance are mid-altitude rainforest (500?600 m), primary lowland rainforest and lowland coastal forest. Unfortunately, it is these habitats that are most threatened by logging operations on the island. In order to aid biodiversity conservation on Choiseul Island we recommend a number of activities including additional biodiversity surveys, increased community awareness and education about biodiversity and the impacts of logging, and the drawing up of a management plan including all terrestrial taxa for Choiseul Island forests.
47
Lee, Seungyeol, e Huifang Xu. "Powder XRD and TEM study on crystal structure and interstratification of Zn-chlorite (baileychlore)". Powder Diffraction 32, n.º 2 (junho de 2017): 118–23. http://dx.doi.org/10.1017/s0885715617000410.
Texto completo da fonteResumo:
Baileychlore is Zn-end member trioctahedral chlorite, named by Audrey C. Rule and Frank Radke in 1988 for the honor of Professor Sturges W. Bailey of the University of Wisconsin – Madison, USA. Baileychlore occurs as dark green chlorite on calcite veins from garnet-vesuvianite skarn clasts at Red Dome ore deposit, Chillagoe, Queensland, Australia. The baileychlore has been studied by using powder X-ray diffraction (XRD), transmission electron microscopy (TEM), and X-ray energy-dispersive analytical electron microscopy analyses to determine crystal structure and interstratified layers. Baileychlore with stacking disorder displays streaking reflections of 0k0 (≠6n) hhl (h ≠ 3n). Unit-cell parameters for baileychlore (type I polytype) with a space group of C$ \bar 1$ are: a = 5.351(3), b = 9.266(5), c = 14.418(8) Å, α = 89.741(3)°, β = 96.741(4)°, and γ = 90.122(2)°. The strong lines of the measured XRD pattern [d(Å)(I)(hkl)] are: 14.331(7.151)(90.5)(002); 4.574(23.2)(1$ \bar 1$0, 11$ \bar 1$); 3.572(38.5)(004); 2.653(31.4)($ \bar 1$31, 200, 13$ \bar 1$); 2.406(49.4)(202, $ \bar 1$33, 13$ \bar 3$); 1.543(27.6)($ \bar 3$31, 060, 33$ \bar 1$), respectively. Reitveld refinement provides a composition (Zn2.49Al0.09Fe2+ 0.09□0.33)0.61− for the octahedral sheet and (Si3.53Al0.47)0.47− for the tetrahedral sheets within the 2:1 layer with (Al1.08Fe1.08Mg0.84)1.08+ for the interlayer sheet. The refinement results indicate that baileychlore is an intergrowth of type I and II polytypes. High-resolution TEM images show stacking disorder of baileychlore with small amount of isolated smectite layers.
48
Pentheroudakis, George, Nikolaos Angouridakis, Ralph Wirtz, Angelos Nikolaou, Konstantine T. Kalogeras, Nicholas Pavlidis e George Fountzilas. "Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome". Journal of Oncology 2009 (2009): 1–10. http://dx.doi.org/10.1155/2009/854127.
Texto completo da fonteResumo:
Locoregional recurrence is the most common failure pattern in patients with head and neck squamous cell carcinoma (HNSCC). We retrospectively identified 41 HNSCC patients with locoregional relapse and used kinetic reverse transcription-polymerase chain reaction (kRT-PCR) in order to study fresh-frozen tumour messenger RNA (mRNA) levels of the Human Epidermal growth factor family members HER1-4, the Vascular Endothelial Growth Factors (VEGFs) A, B, C, D, and their receptors VEGFR1, 2, 3. High VEGF-C and VEGFR3 tumour mRNA expression correlated with relapse beyond the primary locus (neck nodes or soft tissues,P<.05). Tumours with regional nodal involvement at diagnosis more often exhibited high transcriptional activity of VEGFR1 and VEGFR3 at the time of relapse (P<.05). At a median follow-up of 52 months from the time of locoregional recurrence, patients with high VEGF-C tumours at relapse had significantly poorer postrelapse progression-free survival (R-PFS, 5 versus 47 months, log-rankP=.052) and a trend for inferior postrelapse overall survival (R-OS, 22 versus 44 months, log-rankP=.076) in comparison to low VEGF-C tumours. Similar association with dismal outcome was seen for its receptor, VEGFR3 tumoural mRNA levels (log-rankP=.060). In contrast, suppressed tumour transcription of VEGF-D was associated with poorer post-relapse survival, though statistical significance was not reached. Active transcription of the VEGF-C/VEGFR3 axis in recurrent HNSCC is associated with failure at neck soft tissues/lymph nodes and inferior survival post-relapse.
49
Fartun Abdullahi H, OREY, SHEIK MOHAMUD Kadra Hassan, ABDULLE Iftin Abdi Nor, MOHAMOUD Jamal Hassan, GARBA Bashiru, ADAM Mohamed Hussein, DAHIE Hassan Abdullahi, SH NUR Maryan Abdullahi e DIRIE Najib Isse. "BACKSLIDING ON CHILDHOOD IMMUNIZATIONS DUE TO ONGOING COVID-19 PANDEMIC: A RETROSPECTIVE STUDY IN BANADIR REGION, SOMALIA". African Journal of Infectious Diseases 17, n.º 2S (1 de agosto de 2023): 6–12. http://dx.doi.org/10.21010/ajidv17i2s.2.
Texto completo da fonteResumo:
Background: SARS-CoV-2 has resulted in a global public health crisis. During the pandemic, considerable delay was observed making it impossible for some children to receive their due vaccines on time. Like most resource-poor countries, COVID-19 pandemic is thought to have a negative impact on Somalia’s immunization coverage. Materials and methods: This study aimed to assess the impact of the COVID-19 pandemic on routine childhood immunization coverage in Somalia. A retrospective comparative cross-sectional approach was employed to investigate the number of under-5-year children who got their immunization from the two major mother and child hospital, (Banadir and SOS hospitals) in Mogadishu, Somalia from October 2019 to December 2020. To do this, a total of 112, 060 data relating to the routine childhood immunization (measles, polio, whooping cough, hepatitis B, pneumonia, and tuberculosis) were collected from the monthly immunization report-data from the two hospitals. Results: The results showed that all the vaccines except birth vaccines have remarkably dropped with Penta-3 (27%), Penta-2 (11%), measles (10%) and Penta-1 (8%) respectively. However, the birth vaccines (BCG and Polio 0) were not affected as observed in this study. The reduction in children immunization rate in Somalia may be a combination of many other factors, we however recognize that the COVID-19 pandemic may have contributed significantly to this outcome. Conclusion: The government needed to take proactive measures to encourage parents to present their children for immunizations, including increasing community awareness concerning the importance of these routine childhood immunizations despite the ongoing COVID-19 pandemics.
50
Craig, Michael, Sandip Shah, Martin Tallman, Poonam Patil, Jose Easow, Jill Buck, Sachin Shah, Jonathan Lewis e Izidore S. Lossos. "A Phase II Trial of Darinaparsin in Advanced Lymphomas: Report on Safety and Activity." Blood 112, n.º 11 (16 de novembro de 2008): 1562. http://dx.doi.org/10.1182/blood.v112.11.1562.1562.
Texto completo da fonteResumo:
Abstract Darinaparsin (ZIO-101) is a novel organic arsenic molecule that has a mechanism of action mediated by targeted disruption of mitochondrial function, modified signal transduction, and antiangiogenesis. It is active against diverse cancers in vitro. This Phase II multi-center trial is being conducted in patients diagnosed with advanced lymphomas that have received at least 1 prior therapy and require additional treatment. Patients receive 300 mg/m2 of darinaparsin intravenously for 5 consecutive days every 28 days (1 cycle) and are then evaluated for efficacy and safety by standard criteria. Treatment continues until toxicity or progression. To date the study has accrued 22 patients (15 non-Hodgkin’s [NHL], 7 Hodgkin’s); 12 are male and 10 are female. Median age at baseline was 60.5 years (range: 28–80), ECOG performance status was ≤2, and median number of prior therapies was 4 (range 2–6). Thirteen subjects have received at least 2 cycles of darinaparsin and are evaluable for efficacy. Of these, 1 (diagnosed with PTCL) has achieved a complete response (CR) and 3 (diagnosed with marginal zone transformed to diffuse large B-cell, marginal zone, and Hodgkin’s nodular sclerosis, respectively) have achieved partial responses (PRs). These patients had been heavily pretreated (PTCL: CHOP, ICE, and EPOCH; marginal zone transformed to diffuse B-cell: RCHOP, RICE, RT and autologous bone marrow transplantation; marginal zone: rituximab, RCVP, and gemcitabine; and Hodgkin’s: ICE, CBV, gemcitabine+ MDX-060, and stem cell transplant). In the patient with transformed diffuse large B-cell lymphoma who achieved PR, no evidence for macroscopic disease was present, but microscopic low-grade marginal zone lymphoma was detectable in random biopsies from normal-appearing gastric mucosa. In addition, 2 patients (diagnosed with PTCL and Hodgkin’s, respectively) have achieved stable disease (SD). The only Grade 3 adverse event (AE) considered drug-related was wheezing. A total of 12 subjects have reported 37 serious adverse events (SAEs) while on study. Of these, only 2 had SAEs that were considered drug-related (neutropenic fever, fall). In conclusion, darinaparsin has been very well tolerated and has demonstrated promising activity in heavily pretreated patients diagnosed with advanced lymphoma. Initial responses (1 CR, 3 PRs, 2 SDs) have been observed among 13 evaluable patients. Accrual continues; additional safety and efficacy data will be reported.